

The Basophil Surface Marker CD203c Identifies *Aspergillus* Sensitization in Cystic Fibrosis

Bojana Mirković, PhD,^{a,*} Gillian M. Lavelle, BSc,^{a,*} Ahmed Abdul Azim, MB, BCh, BAO, LRCSI&RCPI,^a Kristine Helma, MD,^a Fatma S. Gargoum, MD,^a Kevin Molloy, MB, BCh, BAO,^a Yael Gernez, MD, PhD,^b Katie Dunne, PhD,^c Julie Renwick, PhD,^c Philip Murphy,^c Richard B. Moss, MD,^d Catherine M. Greene, PhD,^a Cedric Gunaratnam, MB,^a Sanjay H. Chotirmall, MD, PhD,^e Noel G. McElvaney MD,^a

^aRespiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland

^bDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA

^cClinical Microbiology Department, Trinity College Dublin, The Adelaide and Meath Hospital incorporating the National Children's Hospital, Tallaght, Dublin, Ireland

^dCenter for Excellence in Pulmonary Biology, Department of Paediatrics, Stanford University School of Medicine, Stanford, CA, USA

^eLee Kong Chian School of Medicine, Nanyang Technological University, Singapore

*Both authors contributed equally to all aspects of this work.

Correspondence and requests for reprints should be addressed to: Sanjay H. Chotirmall, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. E-mail: schotirmall@ntu.edu.sg; Telephone: +65-97537149; Fax: +65-63392889.

25 This work was supported by Science Foundation Ireland *via* a US-Ireland partnership (grant
26 number SFI/08/US/B1676) and by the US Cystic Fibrosis Foundation.

27

Abstract

Background: Colonization by *Aspergillus fumigatus* (*Af*) in cystic fibrosis (CF) may cause *Af* sensitization and/or allergic bronchopulmonary aspergillosis (ABPA) which affects pulmonary function and clinical outcomes. Recent studies show that specific allergens upregulate the surface-expressed basophil marker CD203c in sensitized individuals, a response that can be readily measured by flow cytometry.

Objective: To identify *Af*-sensitization in CF using the basophil activation test (BAT).

Methods: Patients with CF attending Beaumont Hospital were screened for study inclusion. BAT was used to identify *Af* sensitization. Serologic (total IgE and *Af*-specific IgE), pulmonary function and body mass index measurements were performed.

Results: The BAT discriminates *Af*-sensitized from non-sensitized patients with CF. Persistent isolation of *Af* in sputum is a significant risk factor for *Af* sensitization. Levels of the *Af*-stimulated basophil activation marker, CD203c, inversely correlated with pulmonary function and body mass index in *Af*-sensitized but not non-sensitized patients with CF. Total and *Af*-specific IgE, but not IgG, are elevated in *Af*-sensitized CF patients with ABPA when compared to *Af*-sensitized and non-sensitized CF patients without ABPA. Itraconazole treatment did not affect *Af* sensitization.

Conclusion: Combining the BAT with routine serological testing allows classification of patients with CF into three groups: non-sensitized, *Af*-sensitized and ABPA. Accurate and prompt identification of *Af*-associated clinical status may allow early and targeted therapeutic intervention potentially improving clinical outcomes.

Key Messages

- The basophil activation test can identify *Aspergillus fumigatus*-sensitized individuals in the cystic fibrosis population.
- CD203c levels inversely correlate with pulmonary function and body mass index in *A. fumigatus*-sensitized people with cystic fibrosis.
- Prompt identification of *A. fumigatus* sensitization may improve the management of *A. fumigatus*-associated disease in cystic fibrosis.

Capsule Summary

This study demonstrates a novel means of identifying *A. fumigatus* sensitization in cystic fibrosis using the basophil activation test. Simpler classification of *Aspergillus*-associated disease will likely improve both clinical management and outcomes.

Keywords: allergic bronchopulmonary aspergillosis; *Aspergillus fumigatus*; basophil activation test; body mass index; CD203c; cystic fibrosis; flow cytometry; forced expiratory volume in the first second; itraconazole; sensitization.

Abbreviations:

ABPA: allergic bronchopulmonary aspergillosis

Af: *Aspergillus fumigatus*

BAT: basophil activation test

BMI: body mass index

CF: cystic fibrosis

EDTA: ethylenediaminetetraacetic acid

FEV₁: forced expiratory volume in the first second

78 GM: galactomannan
79 MFI: mean fluorescence intensity
80 PWCF: people with CF
81 ROC: receiver-operating characteristic
82 sIgE: specific IgE
83 sIgG: specific IgG
84

INTRODUCTION

Cystic fibrosis (CF) is an inherited disorder characterized by recurrent polymicrobial pulmonary exacerbations and chronic neutrophil-dominated inflammation. Dysfunctional CFTR protein leads to impaired mucociliary clearance and colonization of the CF lung by bacteria and fungi. Much focus has been given to the role of bacteria in the CF airway; however, an increasing recognition of fungi has emerged.¹⁻³ *Aspergillus fumigatus* (*Af*) is the most commonly isolated fungus in CF with a prevalence of up to 60%.⁴ The fungus is associated with a range of manifestations in CF, most commonly allergic bronchopulmonary aspergillosis (ABPA) and less commonly, aspergillomas and invasive pulmonary aspergillosis.⁵⁻⁷

ABPA affects between 2%-15% of patients with CF (PWCF) and recurrent episodes impact pulmonary function.^{1,8-11} It manifests as an allergic, hypersensitive, Th2 CD4⁺ cell-driven response to *Af* and the diagnosis of ABPA in CF is particularly challenging due to overlapping clinical, immunological and radiological features that are similar to those of a pulmonary exacerbation. To address this, consensus conference criteria were published to aid clinicians in diagnosing CF-ABPA.¹² Despite this, inherent weaknesses in these criteria exist. They can be difficult to employ in the CF setting and many CF patients with ABPA do not fulfill these criteria despite a good response to treatment. The criteria have not been updated for 12 years despite advances in both the understanding and the treatment of CF-ABPA. Hence, there is a growing need for a simplified, updated classification to robustly diagnose ABPA, facilitating earlier intervention to improve clinical outcome.

Sensitization is an immunological phenomenon, defined by the production of specific IgE (sIgE). It can arise from a combination of genetic predisposition and allergen exposure.^{13,14} Recent reports show that *Af* sensitization is associated with a greater decline in lung function and an increased rate of pulmonary exacerbations in CF.¹⁵⁻¹⁷ The basophil activation test

110 (BAT) is a novel technique that measures upregulation of CD203c upon stimulation with the
111 specific allergen to which an individual is sensitized.¹⁸ CD203c is an ectonucleotide
112 pyrophosphatase/phosphodiesterase expressed on the surface of basophils, which are
113 important effector cells in type II immune responses.^{18,19} CD203c can be rapidly measured by
114 flow cytometry and has been proposed as a diagnostic tool in atopic disease, including peanut,
115 drug and wasp venom allergy.^{20–22}

116 It has been shown that basophils are primed and hyper-responsive to *Af* allergen stimulation in
117 CF-ABPA.¹⁸ In this current study, BAT to *Af* was employed to identify *Af* sensitization in a
118 CF cohort and it was correlated with key CF clinical measurements. Furthermore, *Af*-
119 stimulated CD203c, in conjunction with commonly available immunological parameters, was
120 examined for use in the classification of patients with CF into non-sensitized, sensitized or
121 ABPA groups.

122

METHODS

Patient recruitment

We prospectively recruited 48 PWCF to the study between October 2012 and October 2014. As controls, 11 healthy non-CF volunteers were also recruited. Ethical approval was obtained from our Institutional Review Board. CF was confirmed by sweat chloride levels (>60 mmol/L) and genotyping. Pulmonary function testing (Online Supplement) and serum sampling was performed on the day of the BAT. Total circulating IgE, sIgE and specific IgG (sIgG) levels to *Af* were determined using the ImmunoCap assay (Phadia, Uppsala, Sweden). Patient demographics are outlined in Supporting Table EI. Quarterly sputum samples were routinely collected for standard microbiological evaluation, including fungi.²³ Exclusion criteria were pregnancy, lung transplantation, peanut allergy and those under 16 years of age.

Cohort characterization

The CF-ABPA cohort was diagnosed as per previously published consensus criteria. Specific IgE (sIgE) levels to *Aspergillus* were used as an alternative to skin prick testing that are interchangeable in consensus criteria.¹² To differentiate between *Af*-sensitized and non-sensitized CF individuals, an arbitrary cut-off (1.36) was set at three standard deviations above the mean value²⁴ of the stimulation index of the healthy control population, with the stimulation index defined as the ratio between *Af*- and PBS-stimulated CD203c values.

Basophil activation test

Samples were processed as previously described.^{18,25,26} Briefly, venous blood was collected in S-Monovette[®] ethylenediaminetetraacetic acid (EDTA) blood tubes (Sarstedt, Germany) and centrifuged at 400g for 10 min at 4 °C. The supernatant was further centrifuged at 3000g for

10 min at 4 °C and 97 µl of platelet-free plasma was added to 100 µl of erythrocyte/leukocyte pellet and incubated for 30 s at 37 °C. Samples were incubated with 3 µl *Af* extract (Mediwiss Analytic GmbH, Moers, Germany) for 10 min at 37 °C. PBS and peanut extract (Mediwiss) were used as controls. Untreated basophils were also evaluated. After washing, cells were stained with FITC mouse anti-human CD3, HLA-DR, CD41a, and CD66b, PerCP-Cy5.5 mouse anti-human CD123 (BD Biosciences, San Jose, CA) and PE mouse anti-human CD203c (Biolegend, San Diego, CA) at saturating concentrations. LIVE/DEAD® FixableNear-IR Dead Cell stain kit (Invitrogen, Carlsbad, CA) was used to distinguish between live and dead cells. After washing, erythrocytes were lysed and leukocytes were fixed with Lyse/Fix buffer (BD Biosciences) for 30 min on ice. After centrifugation at 490g for 5 min, cells were resuspended in 2.5 mM EDTA containing 5 % FCS and analyzed by flow cytometry on a BD FACSCalibur (BD Biosciences) equipped with BD CellQuest Pro Software. Compensation was performed using CaliBRITE Beads (BD Biosciences) and at least 200 basophils per sample were analyzed. Data were analyzed using FlowJo software (Ashland, OR).

Statistical Analysis

Statistical analysis was performed using GraphPad PRISM 4.0 (San Diego, CA). Data were tested for normality using the Kolmogorov-Smirnoff test. Normal data were compared using a two-tailed independent Student's t-test and for non-normal data, the Mann-Whitney U test was performed. Differences were considered significant at $P < 0.05$.

RESULTS

Basophil activation test discriminates between non-sensitized and *Af*-sensitized patients with CF

Flow cytometry was used to measure basophil activation in response to *Af*. Basophils were gated as the Live/Dead⁻/CD3⁻/HLA-DR⁻/CD41a⁻/CD66b⁻/CD123⁺ population and evaluated for CD203c expression following *Af* extract stimulation (Supporting Figure E1). PBS and peanut extract were used as non-offending and immunogenic controls, respectively. To differentiate between *Af*-sensitized and non-sensitized PWCF, an arbitrary cut-off of 1.36 was determined using the stimulation index of the non-CF controls (mean \pm SD = 1.018 \pm 0.114; n = 11). A positivity threshold of three standard deviations above the healthy mean of the stimulation index was determined as before.²⁴ Using this cut-off, 23 (47.9%) of the 48 recruited PWCF were *Af*-sensitized. The ability of sIgE to distinguish between sensitized and non-sensitized individuals has been previously proposed using a cut-off of 0.35 kU/L.¹⁶ The diagnostic performance of the BAT was examined against sensitization status determined with sIgE (*Af* sensitization cut-off 0.35 kU/L; ImmunoCap assay)¹⁶ using receiver-operating characteristic (ROC)-curve analyses. The area under the ROC curve was 0.9134 ($P < 0.0001$; Supporting Figure E2) indicating the excellent discriminating ability of the BAT between non-sensitized and *Af*-sensitized PWCF and corroborating the strength of *Af*-stimulated CD203c levels as an indicator of *Af* sensitization in CF.

***Af*-sensitized PWCF have higher frequency of *Af*-positive sputum cultures compared to non-sensitized PWCF**

Patients with CF were screened for the presence of *Aspergillus* spp. in their quarterly sputum samples as part of routine care, amounting to eight sputum samples from each patient in the

two year period preceding the BAT. Fourteen out of 23 (60.9%) *Af*-sensitized patients, but only 6 out of 25 (24.0 %) non-sensitized PWCF, grew *Af* on at least one occasion in the 2-year period preceding the BAT. *Af*-sensitized PWCF displayed higher frequency of *Af* sputum isolation compared to non-sensitized PWCF ($P = 0.0038$; Figure 1). To verify the specificity of the BAT to *Af*, *Candida albicans* colonization was also assessed. In contrast to *Af*, 19 out of 23 (82.6%) *Af*-sensitized and 17 out of 25 (68.0 %) non-sensitized PWCF grew *C. albicans* at least once in the 2 years preceding the BAT. There was no significant difference in the frequency of *C. albicans* isolation between groups (Supporting Figure E3), illustrating the specificity of the BAT to *Af*. Similar results were observed when colonization with *Pseudomonas aeruginosa* was investigated (Supporting Figure E4). No significant difference in *Af*-stimulated CD203c levels between patients with non-mucoid ($P = 0.3263$) or mucoid *P. aeruginosa* ($P = 0.2351$) compared with their non-colonized counterparts was noted. In summary, BAT to *Af* is specific and PWCF with increased frequency of *Af* in sputum are more likely to develop sensitization to *Af*.

***Af*-stimulated CD203c levels are increased in blood basophils from *Af*-sensitized compared to non-sensitized PWCF**

Af-sensitized PWCF had significantly higher *Af*-stimulated CD203c values compared to healthy controls ($P < 0.0001$) and non-sensitized PWCF ($P < 0.0001$; Figure 2A). Interestingly, *Af*-stimulated CD203c values were significantly higher in *Af*-sensitized PWCF with ABPA than *Af*-sensitized CF individuals without ABPA ($P = 0.0408$; Figure 2B). This demonstrates that the BAT to *Af* distinguishes *Af*-sensitization from non-sensitization along a quantitative spectrum and could also be potentially used in the diagnosis of individuals with ABPA within the *Af*-sensitized cohort.

CD203c expression levels inversely correlate with FEV₁ and BMI of *Af*-sensitized PWCF

Af sensitization has previously been shown to be associated with worse lung function in a variety of pulmonary diseases, including asthma, chronic obstructive pulmonary disease and CF.^{16,17,27,28} We therefore explored the relationship of *Af*-stimulated CD203c levels with lung function (forced expiratory volume in the first second, FEV₁) and body mass index (BMI), both established determinants of mortality in CF.²⁹ We observed a significant correlation of *Af*-stimulated CD203c levels with declining FEV₁ in *Af*-sensitized patients ($n = 16$, $r^2 = 0.6409$, $P = 0.0002$; Figure 3A). Interestingly, no correlation between *Af*-stimulated CD203c values and FEV₁ in non-sensitized PWCF was detected ($n = 25$, $r^2 = 0.0198$, $P = 0.5027$; Figure 3A). CF-ABPA patients receiving corticosteroid treatment were excluded from this analysis due to the potential interference of corticosteroid therapy with CD203c levels (see Supporting Figure E5 and E6). BMI was also shown to inversely correlate with *Af*-stimulated CD203c levels in *Af*-sensitized ($n = 16$, $r^2 = 0.3009$, $P = 0.0278$) but not non-sensitized PWCF ($n = 25$, $r^2 = 0.0905$, $P = 0.1439$; Figure 3B). Together, these data illustrate that *Af*-stimulated CD203c levels correlate with key clinical parameters in CF, including FEV₁ and BMI, confirming the clinical impact of the *Af*-sensitized state.

Total IgE and *Af*-specific IgE, but not *Af*-specific IgG levels, are elevated in serum of *Af*-sensitized patients with ABPA

Total IgE, *Af* sIgE and sIgG levels were evaluated in serum samples from non-sensitized, *Af*-sensitized and CF patients with ABPA. As described above, the stimulation index threshold was used to distinguish sensitized (> 1.36) from non-sensitized (< 1.36) individuals. The CF-ABPA individuals were defined as those meeting classical consensus criteria for ABPA.¹² Total IgE levels were significantly higher in CF-ABPA ($n = 7$) when compared to non-sensitized and *Af*-sensitized PWCF ($n = 25$, $P < 0.0001$ and $n = 16$, $P < 0.0001$, respectively;

Figure 4A). Similarly, when sIgE was assessed, significantly higher levels were observed in CF-ABPA than in non-sensitized and *Af*-sensitized patients with CF ($P = 0.0004$ and $P < 0.0001$, respectively; Figure 4B). *Af*-sensitized PWCF without ABPA had higher sIgE levels than non-sensitized PWCF ($P < 0.0001$). No increase in sIgG levels were observed in the CF-ABPA group when compared to *Af*-sensitized and non-sensitized patients with CF; however, *Af*-sensitized PWCF without ABPA had higher sIgG levels than non-sensitized PWCF ($P = 0.0302$; Figure 4C). Therefore, total serum IgE and sIgE, but not sIgG, are useful in aiding the detection of CF-ABPA in CF and in differentiating it from *Af*-sensitization.

Antifungal therapy does not alter *Af*-stimulated CD203c expression levels on basophils

Recent work by our group has shown that elimination of *Af* bioburden with itraconazole (400 mg daily for 6 weeks) improves clinical outcome.²³ To investigate the effect of fungal eradication on *Af* sensitization, BAT to *Af* was performed. Although we have previously shown that itraconazole reduces the fungal load in sputum,²³ no change to CD203c levels pre- and post itraconazole treatment was observed ($n = 8$, $P = 0.4028$; Figure 5). Additionally, no difference in baseline CD203c expression was observed ($n = 8$, $P = 0.3829$; Supporting Figure E5A). This shows that decreasing the fungal burden in patients with CF undergoing antifungal therapy with itraconazole does not affect *Af* sensitization, once it is established.

Additionally, in a small number of patients ($n = 4$) receiving monthly pulses of high dose intravenous methylprednisolone for ABPA (10-15 mg/kg for three days),³⁰ a trend towards efficacy of treatment was observed with *Af*-stimulated CD203c values halving (57.6%) one week after treatment initiation ($P = 0.1604$, Supporting Figure E6). This trend however decreased to 30% after one month, and prior to the next infusion of corticosteroids ($n = 4$, $P = 0.2672$; Supporting Figure E6), suggestive of the transient effect of corticosteroid therapy with time.

DISCUSSION

The role of bacteria in the CF lung has been extensively studied and potential roles for fungi are beginning to emerge. Recently, much focus has been given to the wide spectrum of *Af*-associated morbidities in CF, including *Af* sensitization and ABPA. Both of these clinical states are associated with poorer clinical outcomes.^{16,31} For this reason, identifying individuals with *Af* sensitization with or without ABPA is important to ensure appropriate and timely therapeutic intervention to minimize pulmonary impact.³⁰ In this study we focused on the basophil activation marker CD203c as an indicator of *Af* sensitization and assessed its effect on important clinical measures of CF disease.

Sensitization to *Af* has previously been associated with poorer lung function,^{16,17} a finding further confirmed by this study. Gernez *et al.*¹⁸ recently reported that basophils from CF-ABPA patients are primed and hyper-responsive to stimulation with *Af* extract. In the current study, we employed the BAT to identify the *Af* sensitization status of our CF cohort. From a logistical viewpoint, the BAT to *Af* can be performed in under 4 hours using a maximum of 2 ml of whole blood. This can be taken in the same blood draw as the routinely measured immunological investigations minimizing discomfort for the patient. A flow cytometer and appropriately trained staff are required to perform the BAT, which would represent the only limitations to its applicability in routine CF centre practice.

Almost half of the patients studied were *Af*-sensitized, which is in accordance with previous studies (31-61%) that employed serology and skin prick testing (SPT) alone.¹⁵⁻¹⁷ Elevated serum IgE to *Af* and SPTs are considered the gold standards for routine laboratory investigations and are part of the established consensus criteria for the diagnosis of ABPA in CF.¹² Nevertheless, both of these tests harbour disadvantages. Specific IgE to *Af* is an easily accessible test for the clinician and is convenient for the patient. It has been shown however, that specific IgE levels tend to change over time and have to be interpreted along with the

296 constellation of other clinical and laboratory variables and patient history to reach a
297 diagnosis.^{32,33} SPTs are often laborious and time consuming as the full investigation may take
298 up to 72 h to complete. Furthermore, subcutaneous injection of the antigen will induce
299 swelling, itching and reddening at the site of injection in an allergic person and is as such a
300 source of discomfort to the patient. The SPTs can be subjective for the attending clinician and
301 open to interpretation as some suggest a wheal diameter of > 3 mm while others recommend a
302 diameter of > 4 mm for a positive result.³² Accumulating reports have shown striking
303 differences in individual patients between SPT and serology test results suggesting an
304 important role for the effector cells of immediate hypersensitivity (mast cells and basophils)
305 and their activation during an allergic response.^{32,34–37} Therefore, there is a great need for a
306 reliable *in vitro* method to complement the routine laboratory tests for sensitization/allergy
307 when the latter show discrepancies or are not feasible.³³ Of note, *Af*-specific IgE levels
308 correlated significantly with CD203c levels (Supporting Figure E7). The BAT is a specific
309 and reliable measure of IgE-dependent response in sensitized individuals because (i) the mast
310 cells are tissue-bound, (ii) the ease of basophil accessibility and (iii) the fact that the
311 upregulation of basophil surface markers can be conveniently measured by flow cytometry.
312 By comparing CD203c levels to the already established cut-off sIgE value of 0.35 kUa/L¹⁶ to
313 distinguish between sensitized and non-sensitized individuals, ROC curve analysis further
314 confirmed the usefulness of the BAT as an indicator of *Af* sensitization in CF. Persistent and
315 prolonged exposure to the fungus is a significant risk factor for *Af*-sensitization as sensitized
316 patients display a higher frequency of *Af* isolation from sputum culture. Although a study by
317 Baxter *et al.*¹⁵ showed no correlation between *Af* colonization and sensitization, it is
318 conceivable that these different outcomes may be related to methodological differences in
319 defining *Af* sensitization, colonization and the microbiological techniques employed.
320 Interestingly, the *Af*-sensitized ABPA cohort had higher *Af*-stimulated CD203c values than

321 *Af*-sensitized patients without ABPA illustrating that levels of measured CD203c may allow
322 differentiation between *Af*-sensitization and CF-ABPA.

323 We and others have previously shown that persistent carriage of *Af* in the CF airway is
324 associated with radiological abnormalities, including more severe bronchiectasis and mosaic
325 pattern perfusion and has an impact on pulmonary function.^{16,38} *Af* sensitization is also
326 associated with lung function decline and increased duration of intravenous antibiotic
327 treatments.^{15,17} In line with this, our data illustrate a significant inverse correlation between
328 *Af*-stimulated CD203c values with FEV₁ and BMI. These findings are in concordance with
329 previously published studies suggesting a negative impact of *Af* sensitization in CF.¹⁵⁻¹⁷ *Af*
330 sensitization likely facilitates CF-ABPA and multiple factors, including degree of fungal
331 exposure, mucus viscosity, immune status, atopy and age may also have interdependent
332 roles.^{12,32,39} Other factors, such as HLA-DR/HLA-DQ subtypes and the presence of single
333 nucleotide polymorphisms in the IL-4 binding site of IL-4 receptor alpha have also been
334 described to associate with development of ABPA.⁴⁰⁻⁴² Longitudinal studies are needed to
335 confirm that *Af* sensitization routinely precedes ABPA.

336 Baxter *et al.*¹¹ have recently proposed a novel classification of aspergillosis in adult CF. Using
337 a combination of serologic (total IgE, *Af* sIgE and sIgG), RT-PCR, and galactomannan (GM)
338 data, they distinguish between non-diseased, CF-ABPA, *Af* sensitization and *Af* bronchitis. In
339 accordance with their findings, we found that CF patients with ABPA had higher total IgE
340 and *Af* sIgE levels compared to non-sensitized and *Af*-sensitized patients without ABPA. Our
341 study showed no difference in sIgG levels between PWCF with or without ABPA.

342 Additionally, when applied to our CF population, both the GM assay and RT-PCR for *Af*
343 detected a high number of *Af*-positive sputum samples (data not shown), preventing adequate
344 differentiation between the cohorts according to the aforementioned classification. This high
345 positivity may be due to the fact that RT-PCR identifies both live and dead organisms,¹⁵ and

that GM assays can yield false-positive results in the presence of penicillin-derived antibiotics, to which many of our patients with CF are exposed.^{43,44} This limits its utility in the current study.

For the purposes of the current study, we adopted a novel, simplified classification that allows differentiation between non-sensitized, *Af*-sensitized and CF-ABPA. We employed a combination of *Af*-stimulated CD203c, total IgE and *Af* sIgE levels (Table I) to identify ABPA, avoiding the need for RT-PCR, GM or *Af* sIgG testing that is not always accessible in CF centers. Elevated *Af*-stimulated CD203c values (> 1.36) combined with elevated serum sIgE (> 1.45 kUa/L) and total IgE (> 185 kU/L) correctly identified all cases of CF-ABPA by the consensus conference criteria. Of note, the sIgE cut-off (1.45 kUa/L) used in the proposed classification system for identification of CF-ABPA is higher than the sIgE cut-off (0.35 kUa/L) routinely used to identify sensitization alone. Furthermore, the total IgE cut-off herein has been considerably reduced compared to consensus values used (minimum 500 kU/L) in line with previously published ROC-curve analysis demonstrating that the optimum level for ABPA diagnosis is >185 kU/L, giving 91% sensitivity and 90% specificity.¹¹ The inclusion of the reduced level in our proposed classification system was validated when one patient meeting our classification criteria for CF-ABPA, *i.e.* elevated CD203c, total IgE and *Af* sIgE, but not consensus conference criteria (total IgE > 500 kU/L), developed ABPA as defined by consensus conference criteria shortly after the study conclusion. A graphical representation of our classification is depicted in Figure 6.

Our previous work has shown that itraconazole alleviates fungal burden in PWCF colonized with *Af*.²³ In this study, itraconazole administration did not influence *Af*-stimulated CD203c levels, suggesting that fungal eradication from the lung does not impact *Af* sensitization once established. Taking into consideration that persistent *Af* colonization is a significant risk factor for sensitization, early itraconazole intervention may be warranted to clear colonization,

371 reduce exposure and thereby minimize the risk of sensitization to *Af*. Acute ABPA flares can
372 be treated with intravenously administered pulsed methylprednisolone at 10-15 mg/kg/day for
373 a three day period every month.^{30,45} Methylprednisolone was administered to four CF-ABPA
374 patients in this study and a trend towards reduction in *Af*-stimulated CD203c values was
375 observed after treatment. However, this trend was not significant ($P = 0.1604$) warranting
376 future longitudinal study with increased numbers to examine the effect of corticosteroid
377 treatment on *Af* sensitization and potentially the use of the BAT to monitor treatment
378 responses. Additionally, future work should also examine the effect of anti-IgE and anti-IL13
379 strategies in the context of CD203c levels and CF-ABPA.

380 In conclusion, we propose a novel and simplified means of identifying sensitization to *Af*
381 using *Af*-stimulated CD203c values. Using the BAT we show that increased incidence of *Af*
382 colonization is associated with *Af* sensitization and the latter state impacts lung function. The
383 practical applicability of the BAT to *Af* in the clinical setting includes an evaluation of *Af*-
384 stimulated CD203c values for patients positive for *Af* on at least two occasions within the
385 preceding two years (Figure 7). If the BAT is negative, itraconazole treatment may be offered
386 for fungal eradication however, a positive result indicates sensitization and a potential
387 increased future risk of ABPA.^{10,16} Consequently, sensitized individuals should have their
388 serology results closely monitored for increases in total IgE or *Af*-sIgE that may indicate
389 ABPA. Despite the lack of effect of azole treatment on the sensitization state, eradication
390 therapy to reduce fungal bioburden may be recommended. If sensitization is a prerequisite for
391 ABPA, corticosteroids may be considered at the early sensitization stage to reduce the
392 likelihood of developing ABPA. A longitudinal study with adequate numbers should be
393 performed to assess the benefits of systemic corticosteroid administration on clinical
394 outcomes in *Aspergillus*-sensitized individuals without ABPA.¹⁷ Timely detection of *Af*

395 sensitization and CF-ABPA equips clinicians to deliver a targeted approach to CF-*Af* therapy
396 to improve clinical outcomes.

397

398 **Acknowledgments**

399 The authors would like to sincerely thank the patients with cystic fibrosis and the healthy
400 volunteers for taking part in this study.

401

References:

1. Chotirmall SH, McElvaney NG. Fungi in the cystic fibrosis lung: Bystanders or pathogens? *Int J Biochem Cell Biol* 2014;52C:161–73.
2. Pohl K, Hayes E, Keenan J, Henry M, Meleady P, Molloy K, et al. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. *Blood* 2014;124:999–1009.
3. Delhaes L, Monchy S, Fréalle E, Hubans C, Salleron J, Leroy S, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community--implications for therapeutic management. *PLoS One* 2012;7:e36313.
4. Mortensen KL, Jensen RH, Johansen HK, Skov M, Pressler T, Howard SJ, et al. *Aspergillus* species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on *Aspergillus fumigatus* azole resistance. *J Clin Microbiol* 2011;49:2243–51.
5. Sabino R, Ferreira JAG, Moss RB, Valente J, Veríssimo C, Carolino E, et al. Molecular epidemiology of *Aspergillus* collected from cystic fibrosis patients. *J Cyst Fibros* 2014;
6. Chotirmall SH, Mirkovic B, Lavelle GM, McElvaney NG. Immuno-evasive *Aspergillus* Virulence Factors. *Mycopathologia* 2014;
7. Chotirmall SH, Al-alawi M, Mirkovic B, Lavelle G, Logan PM, Greene CM, et al. *Aspergillus*-Associated Airway Disease, Inflammation and the Innate Immune Response. *Biomed Res Int* 2013;723129.

- 423 8. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with
424 *Aspergillus fumigatus* on lung function and hospitalization in patients with cystic fibrosis.
425 *Chest* 2010;137:171–6.
- 426 9. Tunnicliffe G, Schomberg L, Walsh S, Tinwell B, Harrison T, Chua F. Airway and
427 parenchymal manifestations of pulmonary aspergillosis. *Respir Med* 2013;107:1113–23.
- 428 10. Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic
429 fibrosis: role of atopy and response to itraconazole. *Chest* 1999;115:364–70.
- 430 11. Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richardson MD, et al. Novel
431 immunologic classification of aspergillosis in adult cystic fibrosis. *J Allergy Clin Immunol*
432 2013;132:560–6.e10.
- 433 12. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al.
434 Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis
435 Foundation Consensus Conference. *Clin Infect Dis* 2003;37 Suppl 3:S225–64.
- 436 13. Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, et al. Fungi and
437 allergic lower respiratory tract diseases. *J Allergy Clin Immunol* 2012;129:280–91; quiz 292–
438 3.
- 439 14. Alesina R, De Amici M, Ciprandi G. Serum IgE discriminates allergy from
440 sensitisation better than skin testing. *Allergol Immunopathol (Madr)* 42:171–3.
- 441 15. Baxter CG, Moore CB, Jones AM, Webb AK, Denning DW. IgE-mediated immune
442 responses and airway detection of *Aspergillus* and *Candida* in adult cystic fibrosis. *Chest*
443 2013;143:1351–7.

- 444 16. Fillaux J, Brémont F, Murris M, Cassaing S, Rittié J-L, Tétu L, et al. Assessment of
445 *Aspergillus* sensitization or persistent carriage as a factor in lung function impairment in
446 cystic fibrosis patients. *Scand J Infect Dis* 2012;44:842–7.
- 447 17. Peetermans M, Goeminne P, De Boeck C, Dupont LJ. IgE sensitization to *Aspergillus*
448 *fumigatus* is not a bystander phenomenon in cystic fibrosis lung disease. *Chest* 2014;146:e99–
449 100.
- 450 18. Gernez Y, Dunn CE, Everson C, Mitsunaga E, Gudiputi L, Krasinska K, et al. Blood
451 basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are
452 primed and hyper-responsive to stimulation by *aspergillus* allergens. *J Cyst Fibros*
453 2012;11:502–10.
- 454 19. Sokol CL, Medzhitov R. Emerging functions of basophils in protective and allergic
455 immune responses. *Mucosal Immunol* 2010;3:129–37.
- 456 20. Santos AF, Douiri A, Bécares N, Wu S-Y, Stephens A, Radulovic S, et al. Basophil
457 activation test discriminates between allergy and tolerance in peanut-sensitized children. *J*
458 *Allergy Clin Immunol* 2014;134:645–52.
- 459 21. Rodríguez-Trabado A, Cámara-Hijón C, Ramos-Cantariño A, Porcel-Carreño SL,
460 Jiménez-Timón S, Pereira-Navarro G, et al. Basophil activation test for the in vitro diagnosis
461 of nonsteroidal anti-inflammatory drug hypersensitivity. *Allergy Asthma Proc* 29:241–9.
- 462 22. Balzer L, Pennino D, Blank S, Seismann H, Darsow U, Schnedler M, et al. Basophil
463 activation test using recombinant allergens: highly specific diagnostic method complementing
464 routine tests in wasp venom allergy. *PLoS One* 2014;9:e108619.

- 465 23. Coughlan CA, Chotirmall SH, Renwick J, Hassan T, Low TB, Bergsson G, et al. The
466 effect of *Aspergillus fumigatus* infection on vitamin D receptor expression in cystic fibrosis.
467 *Am J Respir Crit Care Med* 2012;186:999–1007.
- 468 24. Bergin DA, Reeves EP, Hurley K, Wolfe R, Jameel R, Fitzgerald S, et al. The
469 circulating proteinase inhibitor α -1 antitrypsin regulates neutrophil degranulation and
470 autoimmunity. *Sci Transl Med* 2014;6:217ra1.
- 471 25. Gernez Y, Tirouvanziam R, Yu G, Ghosn EEB, Reshamwala N, Nguyen T, et al.
472 Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab
473 treatment in subjects with nut allergy. *Int Arch Allergy Immunol* 2011;154:318–27.
- 474 26. Gernez Y, Tirouvanziam R, Reshamwala N, Yu G, Weldon BC, Galli SJ, et al.
475 Modulation of mTOR effector phosphoproteins in blood basophils from allergic patients. *J*
476 *Clin Immunol* 2012;32:565–73.
- 477 27. Bafadhel M, McKenna S, Agbetile J, Fairs A, Desai D, Mistry V, et al. *Aspergillus*
478 *fumigatus* during stable state and exacerbations of COPD. *Eur Respir J* 2014;43:64–71.
- 479 28. Menzies D, Holmes L, McCumesky G, Prys-Picard C, Niven R. *Aspergillus*
480 sensitization is associated with airflow limitation and bronchiectasis in severe asthma. *Allergy*
481 2011;66:679–85.
- 482 29. Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, et al. Wasting as
483 an independent predictor of mortality in patients with cystic fibrosis. *Thorax* 2001;56:746–50.
- 484 30. Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, et al.
485 Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic
486 fibrosis. *J Cyst Fibros* 2009;8:253–7.

- 487 31. Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur
488 Respir Rev 2011;20:156–74.
- 489 32. Chotirmall SH, Branagan P, Gunaratnam C, McElvaney NG. Aspergillus/allergic
490 bronchopulmonary aspergillosis in an Irish cystic fibrosis population: a diagnostically
491 challenging entity. Respir Care 2008;53:1035–41.
- 492 33. Chirumbolo S. Basophil activation test in allergy: time for an update? Int Arch Allergy
493 Immunol 2012;158:99–114.
- 494 34. Bousquet J, Lebel B, Dhivert H, Bataille Y, Martinot B, Michel FB. Nasal challenge
495 with pollen grains, skin-prick tests and specific IgE in patients with grass pollen allergy. Clin
496 Allergy 1987;17:529–36.
- 497 35. Niederberger V, Stübner P, Spitzauer S, Kraft D, Valenta R, Ehrenberger K, et al.
498 Skin test results but not serology reflect immediate type respiratory sensitivity: a study
499 performed with recombinant allergen molecules. J Invest Dermatol 2001;117:848–51.
- 500 36. Schoos A-MM, Chawes BLK, Følsgaard N V, Samandari N, Bønnelykke K, Bisgaard
501 H. Disagreement between skin prick test and specific IgE in young children. Allergy
502 2015;70:41–8.
- 503 37. Valent P, Hauswirth AW, Natter S, Sperr WR, Bühring H-J, Valenta R. Assays for
504 measuring in vitro basophil activation induced by recombinant allergens. Methods
505 2004;32:265–70.
- 506 38. McMahon MA, Chotirmall SH, McCullagh B, Branagan P, McElvaney NG, Logan
507 PM. Radiological abnormalities associated with Aspergillus colonization in a cystic fibrosis
508 population. Eur J Radiol 2012;81:e197–202.

- 509 39. Denning DW, Pashley C, Hartl D, Wardlaw A, Godet C, Del Giacco S, et al. Fungal
510 allergy in asthma-state of the art and research needs. *Clin Transl Allergy* 2014;4:14.
- 511 40. Chauhan B, Knutsen A p, Hutcheson PS, Slavin RG, Bellone CJ. T cell subsets,
512 epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary
513 aspergillosis. *J Clin Invest* 1996;97:2324–31.
- 514 41. Chauhan B, Santiago L, Kirschmann DA, Hauptfeld V, Knutsen AP, Hutcheson PS, et
515 al. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary
516 aspergillosis. *J Immunol* 1997;159:4072–6.
- 517 42. Knutsen AP, Kariuki B, Consolino JD, Warrier MR. IL-4 alpha chain receptor (IL-
518 4Ralpha) polymorphisms in allergic bronchopulmonary sspergillosis. *Clin Mol Allergy*
519 2006;4:3.
- 520 43. Zandijk E, Mewis A, Magerman K, Cartuyvels R. False-positive results by the platelia
521 Aspergillus galactomannan antigen test for patients treated with amoxicillin-clavulanate. *Clin*
522 *Vaccine Immunol* 2008;15:1132–3.
- 523 44. Boonsarngsuk V, Niyompattama A, Teosirimongkol C, Sriwanichrak K. False-
524 positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by
525 different antibiotics. *Scand J Infect Dis* 2010;42:461–8.
- 526 45. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, et al.
527 Antibiotic Management of Lung Infections in Cystic Fibrosis. II. Nontuberculous
528 Mycobacteria, Anaerobic Bacteria, and Fungi. *Ann Am Thorac Soc* 2014;11:1298–306.
- 529

Tables

TABLE I. Simplified classification of *Aspergillus*-associated disease in CF.

Cut-off	<i>Af</i>-stimulated CD203c 1.36 ^a	sIgE 1.45 kUa/L ^b	Total IgE 185 kU/L ^c
Non-sensitized group	↓	↓	↓
<i>Af</i>-sensitized group	↑	↓	↓
CF-ABPA group	↑	↑	↑

^aDetermined as described in the methods section. ^b Local cut-off value. ^cAs proposed by Baxter *et al.*.¹¹

Figure legends

Figure 1. Frequency of *Af*-positive sputum cultures in non-sensitized PWCF (CF *Af*-sensitized-; n = 25) and *Af*-sensitized (CF *Af*-sensitized+; n = 23) in the two year period preceding the BAT. PWCF were screened for *Af* in sputum as a part of routine care. Data are presented as means \pm standard error of mean. **p<0.01.

Figure 2. *Af*-stimulated CD203c levels in non-sensitized, *Af*-sensitized and ABPA PWCF. (A) PWCF were classified as non-sensitized (n = 25) or *Af*-sensitized (n = 23). (B) The *Af*-sensitized cohort was further divided into those with (*Af*-sensitized+ ABPA+; n=7) or without ABPA (*Af*-sensitized+ ABPA-; n=16). Data are presented as Tukey box plots and the median is represented by the middle line. *p<0.05, *p<0.001.**

Figure 3. Correlation of *Af*-stimulated CD203c levels with FEV₁ and BMI. *Af*-stimulated CD203c levels correlated with (A) FEV₁ ($r^2 = 0.6409$, $P = 0.0002$) and (B) BMI ($r^2 = 0.3009$, $P = 0.0278$) in *Af*-sensitized (n = 16) but not in non-sensitized PWCF (FEV₁; n = 25, $r^2 = 0.0198$, $P = 0.5027$ and BMI; $r^2 = 0.0905$, $P = 0.1439$).

Figure 4. Serologic immune parameters in PWCF according to *Af* sensitization status. (A) Total IgE, (B) sIgE and (C) sIgG serum levels were measured in non-sensitized (n = 25), *Af*-sensitized (n = 16) and CF ABPA patients (n = 7). Data are presented as Tukey box plots and the median is represented by the middle line. *p<0.05, *p<0.001.**

Figure 5. Effect of itraconazole treatment on *Af*-stimulated CD203c levels in PWCF. *Af*-stimulated CD203c levels in blood basophils from PWCF before and after 6 weeks of

treatment with oral itraconazole ($n = 8$, $P = 0.4028$) are presented as Tukey box plots and the line in the middle of the box represents the median.

Figure 6. Graphical representation of a simplified classification of *Aspergillus*-associated disease using a combination of *Af*-stimulated CD203c, total IgE and sIgE levels. The blue, red and green dots denote non-sensitized ($n=25$), *Af*-sensitized ($n=16$) and PWCF with ABPA ($n=7$), respectively as depicted with 3D scatter plot.

Figure 7. A schematic diagram illustrating the potential stages of *Aspergillus*-associated CF disease with detection methods and possible treatment interventions at each stage. Solid and hashed lines represent established and suggested treatment regimens, respectively.

Figures





Figure 1.

580




581

582

583 **Figure 2.**

584

585




586

587

588 **Figure 3.**

589

590



591


592

593

594 **Figure 4.**

595

596



597

598

599 **Figure 5.**

600




Figure 6.




Figure 7.